
An audit finding is cheap. What it costs is determined entirely by what happens next. Inspectors across GMP, GDP, pharmacovigilance and medical device frameworks pay[…]

Manufacturing is audited. Laboratories are audited. Pharmacovigilance is audited because the law requires it. Regulatory affairs — the function that owns the dossier, the commitments,[…]

Chapter 9 of the EU GMP Guide is one of the shortest chapters in the guide and one of the most revealing. Self-inspection is the[…]

Cosmetics are not authorised before they reach the EU market, and that absence of a pre-approval step misleads people about how regulated the sector actually[…]

A medical device manufacturer selling into Europe and the United States is now audited against a quality system standard that both jurisdictions recognise. Since 2[…]

Auditing your pharmacovigilance system is not optional and not a quality-department formality. It is a legal obligation on the marketing authorisation holder, its results are[…]

Most regulated companies now run at least one GxP-critical process on software they do not host, cannot inspect directly, and cannot stop from updating. That[…]

Data integrity findings rarely arise because a company set out to falsify anything. They arise because nobody was looking. A system generates an audit trail,[…]

For two decades, validating software used in production and quality systems meant generating documentation — often a great deal of it, and often with little[…]

Almost every GxP decision a company makes today rests on data produced, stored or transformed by a computerised system. Regulators have responded by treating those[…]